The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Noninvasive Delivery Vaccine Market Research Report 2024
Synopsis
Noninvasive vaccine delivery systems need to incorporate an effective adjuvant, specially designed for triggering both mucosal and systemic immune responses.
Global Noninvasive Delivery Vaccine market is projected to reach US$ 3909.1 million in 2029, increasing from US$ 2670 million in 2022, with the CAGR of 5.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Noninvasive Delivery Vaccine market research.
The oral vaccination market is primarily driven by the advantages it offers in terms of ease of administration, increased patient compliance, and cost-effectiveness compared to traditional injectable vaccines. Oral vaccines provide a non-invasive and painless immunization method, particularly beneficial for pediatric and elderly populations. Additionally, their potential to elicit both systemic and mucosal immunity enhances protection against pathogens that enter the body through mucosal surfaces, such as the respiratory and gastrointestinal tracts, further fueling their adoption. However, the market also faces challenges, including the complex formulation and delivery of oral vaccines, which may affect their stability and efficacy. Developing vaccines that can withstand acidic environments and enzymatic degradation in the gastrointestinal tract poses significant scientific and manufacturing challenges. Moreover, gaining regulatory approvals and ensuring public acceptance of oral vaccines may require extensive clinical data and educational efforts to dispel misconceptions about their safety and efficacy. To overcome these challenges, the industry is focused on research and innovation to improve oral vaccine formulation and delivery technologies. Collaborations between vaccine developers, research institutions, and regulatory authorities are crucial in driving the growth of the oral vaccination market and expanding access to effective and accessible immunization options, particularly in regions with limited healthcare infrastructure.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Noninvasive Delivery Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
AstraZeneca
Cipla
BCHT
Segment by Type
Oral Vaccine
Nasal Spray Vaccine
Segment by Application
Public
Private
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Noninvasive Delivery Vaccine report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Noninvasive vaccine delivery systems need to incorporate an effective adjuvant, specially designed for triggering both mucosal and systemic immune responses.
Global Noninvasive Delivery Vaccine market is projected to reach US$ 3909.1 million in 2029, increasing from US$ 2670 million in 2022, with the CAGR of 5.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Noninvasive Delivery Vaccine market research.
The oral vaccination market is primarily driven by the advantages it offers in terms of ease of administration, increased patient compliance, and cost-effectiveness compared to traditional injectable vaccines. Oral vaccines provide a non-invasive and painless immunization method, particularly beneficial for pediatric and elderly populations. Additionally, their potential to elicit both systemic and mucosal immunity enhances protection against pathogens that enter the body through mucosal surfaces, such as the respiratory and gastrointestinal tracts, further fueling their adoption. However, the market also faces challenges, including the complex formulation and delivery of oral vaccines, which may affect their stability and efficacy. Developing vaccines that can withstand acidic environments and enzymatic degradation in the gastrointestinal tract poses significant scientific and manufacturing challenges. Moreover, gaining regulatory approvals and ensuring public acceptance of oral vaccines may require extensive clinical data and educational efforts to dispel misconceptions about their safety and efficacy. To overcome these challenges, the industry is focused on research and innovation to improve oral vaccine formulation and delivery technologies. Collaborations between vaccine developers, research institutions, and regulatory authorities are crucial in driving the growth of the oral vaccination market and expanding access to effective and accessible immunization options, particularly in regions with limited healthcare infrastructure.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Noninvasive Delivery Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
AstraZeneca
Cipla
BCHT
Segment by Type
Oral Vaccine
Nasal Spray Vaccine
Segment by Application
Public
Private
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Noninvasive Delivery Vaccine report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Noninvasive Delivery Vaccine Market Overview
1.1 Product Overview and Scope of Noninvasive Delivery Vaccine
1.2 Noninvasive Delivery Vaccine Segment by Type
1.2.1 Global Noninvasive Delivery Vaccine Market Value Comparison by Type (2023-2029)
1.2.2 Oral Vaccine
1.2.3 Nasal Spray Vaccine
1.3 Noninvasive Delivery Vaccine Segment by Application
1.3.1 Global Noninvasive Delivery Vaccine Market Value by Application: (2023-2029)
1.3.2 Public
1.3.3 Private
1.4 Global Noninvasive Delivery Vaccine Market Size Estimates and Forecasts
1.4.1 Global Noninvasive Delivery Vaccine Revenue 2018-2029
1.4.2 Global Noninvasive Delivery Vaccine Sales 2018-2029
1.4.3 Global Noninvasive Delivery Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Noninvasive Delivery Vaccine Market Competition by Manufacturers
2.1 Global Noninvasive Delivery Vaccine Sales Market Share by Manufacturers (2018-2023)
2.2 Global Noninvasive Delivery Vaccine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Noninvasive Delivery Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global Noninvasive Delivery Vaccine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Noninvasive Delivery Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Noninvasive Delivery Vaccine, Product Type & Application
2.7 Noninvasive Delivery Vaccine Market Competitive Situation and Trends
2.7.1 Noninvasive Delivery Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Noninvasive Delivery Vaccine Players Market Share by Revenue
2.7.3 Global Noninvasive Delivery Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Noninvasive Delivery Vaccine Retrospective Market Scenario by Region
3.1 Global Noninvasive Delivery Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Noninvasive Delivery Vaccine Global Noninvasive Delivery Vaccine Sales by Region: 2018-2029
3.2.1 Global Noninvasive Delivery Vaccine Sales by Region: 2018-2023
3.2.2 Global Noninvasive Delivery Vaccine Sales by Region: 2024-2029
3.3 Global Noninvasive Delivery Vaccine Global Noninvasive Delivery Vaccine Revenue by Region: 2018-2029
3.3.1 Global Noninvasive Delivery Vaccine Revenue by Region: 2018-2023
3.3.2 Global Noninvasive Delivery Vaccine Revenue by Region: 2024-2029
3.4 North America Noninvasive Delivery Vaccine Market Facts & Figures by Country
3.4.1 North America Noninvasive Delivery Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Noninvasive Delivery Vaccine Sales by Country (2018-2029)
3.4.3 North America Noninvasive Delivery Vaccine Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Noninvasive Delivery Vaccine Market Facts & Figures by Country
3.5.1 Europe Noninvasive Delivery Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Noninvasive Delivery Vaccine Sales by Country (2018-2029)
3.5.3 Europe Noninvasive Delivery Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Noninvasive Delivery Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Noninvasive Delivery Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Noninvasive Delivery Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Noninvasive Delivery Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Noninvasive Delivery Vaccine Market Facts & Figures by Country
3.7.1 Latin America Noninvasive Delivery Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Noninvasive Delivery Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Noninvasive Delivery Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Noninvasive Delivery Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Noninvasive Delivery Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Noninvasive Delivery Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Noninvasive Delivery Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Noninvasive Delivery Vaccine Sales by Type (2018-2029)
4.1.1 Global Noninvasive Delivery Vaccine Sales by Type (2018-2023)
4.1.2 Global Noninvasive Delivery Vaccine Sales by Type (2024-2029)
4.1.3 Global Noninvasive Delivery Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Noninvasive Delivery Vaccine Revenue by Type (2018-2029)
4.2.1 Global Noninvasive Delivery Vaccine Revenue by Type (2018-2023)
4.2.2 Global Noninvasive Delivery Vaccine Revenue by Type (2024-2029)
4.2.3 Global Noninvasive Delivery Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Noninvasive Delivery Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global Noninvasive Delivery Vaccine Sales by Application (2018-2029)
5.1.1 Global Noninvasive Delivery Vaccine Sales by Application (2018-2023)
5.1.2 Global Noninvasive Delivery Vaccine Sales by Application (2024-2029)
5.1.3 Global Noninvasive Delivery Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Noninvasive Delivery Vaccine Revenue by Application (2018-2029)
5.2.1 Global Noninvasive Delivery Vaccine Revenue by Application (2018-2023)
5.2.2 Global Noninvasive Delivery Vaccine Revenue by Application (2024-2029)
5.2.3 Global Noninvasive Delivery Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Noninvasive Delivery Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Merck Noninvasive Delivery Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 GSK Noninvasive Delivery Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Sanofi Noninvasive Delivery Vaccine Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Lanzhou Institute
6.4.1 Lanzhou Institute Corporation Information
6.4.2 Lanzhou Institute Description and Business Overview
6.4.3 Lanzhou Institute Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Lanzhou Institute Noninvasive Delivery Vaccine Product Portfolio
6.4.5 Lanzhou Institute Recent Developments/Updates
6.5 Serum Institute
6.5.1 Serum Institute Corporation Information
6.5.2 Serum Institute Description and Business Overview
6.5.3 Serum Institute Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Serum Institute Noninvasive Delivery Vaccine Product Portfolio
6.5.5 Serum Institute Recent Developments/Updates
6.6 Valneva
6.6.1 Valneva Corporation Information
6.6.2 Valneva Description and Business Overview
6.6.3 Valneva Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Valneva Noninvasive Delivery Vaccine Product Portfolio
6.6.5 Valneva Recent Developments/Updates
6.7 Shanghai United Cell
6.6.1 Shanghai United Cell Corporation Information
6.6.2 Shanghai United Cell Description and Business Overview
6.6.3 Shanghai United Cell Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Shanghai United Cell Noninvasive Delivery Vaccine Product Portfolio
6.7.5 Shanghai United Cell Recent Developments/Updates
6.8 Bibcol
6.8.1 Bibcol Corporation Information
6.8.2 Bibcol Description and Business Overview
6.8.3 Bibcol Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Bibcol Noninvasive Delivery Vaccine Product Portfolio
6.8.5 Bibcol Recent Developments/Updates
6.9 PaxVax
6.9.1 PaxVax Corporation Information
6.9.2 PaxVax Description and Business Overview
6.9.3 PaxVax Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.9.4 PaxVax Noninvasive Delivery Vaccine Product Portfolio
6.9.5 PaxVax Recent Developments/Updates
6.10 Vabiotech
6.10.1 Vabiotech Corporation Information
6.10.2 Vabiotech Description and Business Overview
6.10.3 Vabiotech Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Vabiotech Noninvasive Delivery Vaccine Product Portfolio
6.10.5 Vabiotech Recent Developments/Updates
6.11 Tiantan Biological
6.11.1 Tiantan Biological Corporation Information
6.11.2 Tiantan Biological Noninvasive Delivery Vaccine Description and Business Overview
6.11.3 Tiantan Biological Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Tiantan Biological Noninvasive Delivery Vaccine Product Portfolio
6.11.5 Tiantan Biological Recent Developments/Updates
6.12 EuBiologics
6.12.1 EuBiologics Corporation Information
6.12.2 EuBiologics Noninvasive Delivery Vaccine Description and Business Overview
6.12.3 EuBiologics Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.12.4 EuBiologics Noninvasive Delivery Vaccine Product Portfolio
6.12.5 EuBiologics Recent Developments/Updates
6.13 Panacea Biotec Ltd
6.13.1 Panacea Biotec Ltd Corporation Information
6.13.2 Panacea Biotec Ltd Noninvasive Delivery Vaccine Description and Business Overview
6.13.3 Panacea Biotec Ltd Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Panacea Biotec Ltd Noninvasive Delivery Vaccine Product Portfolio
6.13.5 Panacea Biotec Ltd Recent Developments/Updates
6.14 Bio-Med
6.14.1 Bio-Med Corporation Information
6.14.2 Bio-Med Noninvasive Delivery Vaccine Description and Business Overview
6.14.3 Bio-Med Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Bio-Med Noninvasive Delivery Vaccine Product Portfolio
6.14.5 Bio-Med Recent Developments/Updates
6.15 Halfkin Bio-Pharmaceuticals
6.15.1 Halfkin Bio-Pharmaceuticals Corporation Information
6.15.2 Halfkin Bio-Pharmaceuticals Noninvasive Delivery Vaccine Description and Business Overview
6.15.3 Halfkin Bio-Pharmaceuticals Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Halfkin Bio-Pharmaceuticals Noninvasive Delivery Vaccine Product Portfolio
6.15.5 Halfkin Bio-Pharmaceuticals Recent Developments/Updates
6.16 AstraZeneca
6.16.1 AstraZeneca Corporation Information
6.16.2 AstraZeneca Noninvasive Delivery Vaccine Description and Business Overview
6.16.3 AstraZeneca Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.16.4 AstraZeneca Noninvasive Delivery Vaccine Product Portfolio
6.16.5 AstraZeneca Recent Developments/Updates
6.17 Cipla
6.17.1 Cipla Corporation Information
6.17.2 Cipla Noninvasive Delivery Vaccine Description and Business Overview
6.17.3 Cipla Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Cipla Noninvasive Delivery Vaccine Product Portfolio
6.17.5 Cipla Recent Developments/Updates
6.18 BCHT
6.18.1 BCHT Corporation Information
6.18.2 BCHT Noninvasive Delivery Vaccine Description and Business Overview
6.18.3 BCHT Noninvasive Delivery Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.18.4 BCHT Noninvasive Delivery Vaccine Product Portfolio
6.18.5 BCHT Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Noninvasive Delivery Vaccine Industry Chain Analysis
7.2 Noninvasive Delivery Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Noninvasive Delivery Vaccine Production Mode & Process
7.4 Noninvasive Delivery Vaccine Sales and Marketing
7.4.1 Noninvasive Delivery Vaccine Sales Channels
7.4.2 Noninvasive Delivery Vaccine Distributors
7.5 Noninvasive Delivery Vaccine Customers
8 Noninvasive Delivery Vaccine Market Dynamics
8.1 Noninvasive Delivery Vaccine Industry Trends
8.2 Noninvasive Delivery Vaccine Market Drivers
8.3 Noninvasive Delivery Vaccine Market Challenges
8.4 Noninvasive Delivery Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
